Private: Fullwidth Portfolio Post

Home News CADTH

31

Jan2024

CADTH Update Introduces Streamlined Economic Reports and Launches BIA Template Consultation

On Friday, CADTH’s Pharmaceutical Reviews Update – Issue 43 introduced a number of updates pertaining to its Reimbursement Reviews procedures. These include: Budget Impact Analysis (BIA) Consultation: CADTH is seeking stakeholder feedback on its draft BIA template tool. The tool is an optional resource to ... Read More

11

Jul2023

CADTH Announces Changes to Reimbursement Reviews Process & Fee Schedule Update

On June 5, 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced a series of process improvements it plans to explore or add to its drug reimbursement review process. These changes - aimed at gaining efficiencies, reducing timelines and improving transparency – include:... Read More

01

May2023

Connect with PDCI Market Access at the CADTH Symposium in Ottawa, May 16-18, 2023

PDCI Market Access is proud to announce is participation as a Platinum Sponsor of the 2023 CADTH Symposium taking place in Ottawa on May16-18, 2023. Join PDCI’s Courtney Abunassar on May 17 at 1 p.m. during Oral Presentations 3 – Policy Issues for a ... Read More

01

Mar2023

INESSS Fee Schedule Update; Upcoming CADTH Consultation and Application Process Updates

INESSS has published its updated fee schedule for its scientific evaluation of drugs, stable blood products and technologies in the February 18, 2023 Gazette du Québec. Fees for all submission types have increased 6.44% as of January 1, 2023, bringing fees to: $63,791 for a new ... Read More

05

Dec2022

CADTH Pharmaceutical Reviews Update Includes Launch of RWE Guidance Consultation

On November 10, 2022, among other procedural updates included in the CADTH Pharmaceutical Reviews Update Issue 32, CADTH published its Real-World Evidence (RWE) Steering Committee’s anticipated Proposed RWE Reporting Guidance and initiated a public consultation on the guidance open now through January 6, 2023.What to know: The ... Read More

22

Nov2022

CADTH Pharmaceutical Reviews Update Includes Launch of RWE Guidance Consultation

On November 10, 2022, among other procedural updates included in the CADTH Pharmaceutical Reviews Update Issue 32, CADTH published its Real-World Evidence (RWE) Steering Committee’s anticipated Proposed RWE Reporting Guidance and initiated a public consultation on the guidance open now through January 6, 2023.What to know: The ... Read More

05

May2022

CADTH Update: Advice on Real-World Evidence (RWE) by Scientific Advice Program

On May 3, 2022, CADTH announced the mandate expansion of the Scientific Advice Program to include advice on RWE generation plans after protocols for pivotal trials are finalized. What to know: The expanded program will run for a 1-year learning ... Read More

11

Apr2022

CADTH: New Clinical Evidence Template Requirement for October 2022 Submissions

The Canadian Agency for Drugs and Technologies in Health (CADTH) has published Issue 28 of its Pharmaceutical Reviews Update. Below PDCI has summarized the updates and clarifications, and provided implications for manufacturers. CADTH’s update also includes two consultations open until April 14, one concerning a streamlined drug class ... Read More

17

Dec2021

CADTH Pharmaceutical Reviews Update- Issue 27

On December 16, 2021, CADTH provided an update regarding CADTH’s drug review programs. A. Expanded Provisional Funding Algorithm Process CADTH has expanded the provisional funding algorithm process to include a new rapid algorithm process. This rapid algorithm process will be ... Read More

20

May2021

PDCI at ISPOR: Poster Presentation on Oncology Companion Diagnostics

ISPOR 2021 runs between May 17-20 with the theme of HEOR: Evolving for Tomorrow's Challenges. During the conference, PDCI Market Access will be presenting a poster titled: Identification of Gaps and Opportunities for Provincial Reimbursement of Oncology Companion Diagnostics in Canada on May 18th 2021 from 11:30:00 AM ... Read More